Drug Type Small molecule drug |
Synonyms SH748M, SHC 014748M, SHC-014748M + [1] |
Target |
Mechanism PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | CN | 19 Jul 2022 | |
Small Lymphocytic Lymphoma | Phase 2 | CN | 19 Jul 2022 | |
Peripheral T-Cell Lymphoma | Phase 2 | - | 01 Aug 2020 | |
T-cell lymphoma recurrent | Phase 2 | - | 01 Aug 2020 | |
Follicular Lymphoma | Phase 2 | CN | 23 Jun 2020 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | CN | 09 May 2020 | |
Refractory Follicular Lymphoma | Phase 2 | CN | 09 May 2020 | |
Indolent Non-Hodgkin Lymphoma | Phase 1 | CN | 19 Apr 2022 | |
B-Cell Lymphoma | Phase 1 | CN | 07 Sep 2018 | |
B-Cell Malignant Neoplasm | Phase 1 | CN | 07 Sep 2018 |
NCT03588598 (ASH2019) Manual | Phase 1 | 38 | ugjtfichbu(mfvtkyxkop) = none zthkdvfypo (wryecrdsfi ) View more | Positive | 13 Nov 2019 |